CA2369893A1 - Vegf responsive cell-based assay for determining vegf bioactivity - Google Patents
Vegf responsive cell-based assay for determining vegf bioactivity Download PDFInfo
- Publication number
- CA2369893A1 CA2369893A1 CA002369893A CA2369893A CA2369893A1 CA 2369893 A1 CA2369893 A1 CA 2369893A1 CA 002369893 A CA002369893 A CA 002369893A CA 2369893 A CA2369893 A CA 2369893A CA 2369893 A1 CA2369893 A1 CA 2369893A1
- Authority
- CA
- Canada
- Prior art keywords
- vegf
- activity
- vector
- candidate compound
- reporter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000423 cell based assay Methods 0.000 title abstract description 4
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 title 2
- 101150030763 Vegfa gene Proteins 0.000 title 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 79
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 21
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 76
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 38
- 108091008605 VEGF receptors Proteins 0.000 claims description 37
- 108060001084 Luciferase Proteins 0.000 claims description 32
- 230000000694 effects Effects 0.000 claims description 24
- 239000013598 vector Substances 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 12
- 230000004568 DNA-binding Effects 0.000 claims description 11
- 102100039556 Galectin-4 Human genes 0.000 claims description 11
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 claims description 11
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 9
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 7
- 230000027455 binding Effects 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 102000043136 MAP kinase family Human genes 0.000 claims description 6
- 108091054455 MAP kinase family Proteins 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 2
- 108091023040 Transcription factor Proteins 0.000 claims 2
- 102000040945 Transcription factor Human genes 0.000 claims 2
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims 2
- 230000000865 phosphorylative effect Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 11
- 230000019491 signal transduction Effects 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 70
- 239000005089 Luciferase Substances 0.000 description 32
- 238000004519 manufacturing process Methods 0.000 description 16
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 238000011533 pre-incubation Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108010084455 Zeocin Proteins 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000010595 endothelial cell migration Effects 0.000 description 2
- 102000007656 ets-Domain Protein Elk-1 Human genes 0.000 description 2
- 108010032461 ets-Domain Protein Elk-1 Proteins 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000004364 Benzylated hydrocarbon Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101000827746 Homo sapiens Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012577 media supplement Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A VEGF responsive cell-based assay for determining VEGF bioactivity is disclosed. The assay utilizes established signal transduction pathways in a method for determining VEGF bioactivity in a sample.
Description
FIELD OF THE INVENTION
The present invention generally relates to detection-of vascular endothelial growth factor (VEGF) in a sample. Specifically; the present invention relates to a VEGF responsive cell-based assay for use in the measurement of the biological activity of VEGF.
A number of biological properties: have been described for VEGF, including the promotion of angiogenesis. Other properties include endothelial cell migration; endothelial cell proliferation, in vitro capillary tube formation, inhibitionof endothelial cell apoptosis, and increased in vivo vascular permeability producing edema.
Because VEGF appears tQ have a number of significant biological properties; assays for he: detection of VEGF and its :properties have become increasingly important:
One in vitro bioassay :avhioh has been developed is based on the ability of human umbilical vein endothelial cells (I-iUVEC) to migrate in response to VEGF.
This bioassay includes the'steps of first virally transfecting Rat-2 cells with the consequent production of VEGF protein, and: then testing he produced protein extract for the ability to stimulate HUVEC migration. While this assay can be utilized to demonstrate endothelial cell migration stimulated by VEGF protein in the conditioned media of cells, this assay includes a number of time-consuming steps, which cannot easily be automated.
Recently, it was proposed that VEGF could be a marker of cardiovascular disease risk in patients with hypertension. The measurement of a patient's VEGF
andlor FLT-2 levels may be an indicator of the effectiveness of a hypertensive therapy.
The present invention generally relates to detection-of vascular endothelial growth factor (VEGF) in a sample. Specifically; the present invention relates to a VEGF responsive cell-based assay for use in the measurement of the biological activity of VEGF.
A number of biological properties: have been described for VEGF, including the promotion of angiogenesis. Other properties include endothelial cell migration; endothelial cell proliferation, in vitro capillary tube formation, inhibitionof endothelial cell apoptosis, and increased in vivo vascular permeability producing edema.
Because VEGF appears tQ have a number of significant biological properties; assays for he: detection of VEGF and its :properties have become increasingly important:
One in vitro bioassay :avhioh has been developed is based on the ability of human umbilical vein endothelial cells (I-iUVEC) to migrate in response to VEGF.
This bioassay includes the'steps of first virally transfecting Rat-2 cells with the consequent production of VEGF protein, and: then testing he produced protein extract for the ability to stimulate HUVEC migration. While this assay can be utilized to demonstrate endothelial cell migration stimulated by VEGF protein in the conditioned media of cells, this assay includes a number of time-consuming steps, which cannot easily be automated.
Recently, it was proposed that VEGF could be a marker of cardiovascular disease risk in patients with hypertension. The measurement of a patient's VEGF
andlor FLT-2 levels may be an indicator of the effectiveness of a hypertensive therapy.
-2.
Currently; with the seemingly greater importance of VEGF; it would be both advantageous and desirable to have a VEGF responsive assay that is less complex than previous assays, that can be automated, and that-is also directly linked to a reporter protein tied-to the VEGF receptor (VEGF-R)/FLK-1 signal transduction pathway.
SUMMARY OF THE INVENTION
The present invention provides a method for determining VEGF' activity in a sample.
The present invention also relates to a secondary screen which is useful for identifying compounds that modulate VEGF receptors.
The present invention also provides a primary screening mechanism for screening .compounds as inhibitors of VEGF function:
The present invention also provides a stable cell line for use in determining VEGF bioactivity and for use in screening compounds which modulate VEGF
function or VEGF receptor function>
BRIEF DESCRIPTION OF THE FIGURES
Ether advantages of the present invention will be readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings wherein:
Figure la is a graph illustrating a VEGF responsive assay wherein the effects of various serum preincubation conditions are shown as a function of increased luciferase expression wherein cells were seeded 24 hours prior ao VEGF' addition and were harvested 48 hours after VEGF addition;
Figure 1 b is a ,graph illustrating a VEGF responsive assay similar to that shown in Figure I a wherein. the concentration of VEGF utilized in the assay was increased to 50 ng/mL as opposed to 25 ng/mL in Figure la;
Currently; with the seemingly greater importance of VEGF; it would be both advantageous and desirable to have a VEGF responsive assay that is less complex than previous assays, that can be automated, and that-is also directly linked to a reporter protein tied-to the VEGF receptor (VEGF-R)/FLK-1 signal transduction pathway.
SUMMARY OF THE INVENTION
The present invention provides a method for determining VEGF' activity in a sample.
The present invention also relates to a secondary screen which is useful for identifying compounds that modulate VEGF receptors.
The present invention also provides a primary screening mechanism for screening .compounds as inhibitors of VEGF function:
The present invention also provides a stable cell line for use in determining VEGF bioactivity and for use in screening compounds which modulate VEGF
function or VEGF receptor function>
BRIEF DESCRIPTION OF THE FIGURES
Ether advantages of the present invention will be readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings wherein:
Figure la is a graph illustrating a VEGF responsive assay wherein the effects of various serum preincubation conditions are shown as a function of increased luciferase expression wherein cells were seeded 24 hours prior ao VEGF' addition and were harvested 48 hours after VEGF addition;
Figure 1 b is a ,graph illustrating a VEGF responsive assay similar to that shown in Figure I a wherein. the concentration of VEGF utilized in the assay was increased to 50 ng/mL as opposed to 25 ng/mL in Figure la;
Figure 2 is a graph illustrating the effects of cell density and VEGF 121 concentration on luciferase expression in a VEGF receptor stable transfected Hela-Luciferase HLR-ELK-1 cell line;
Figure 3 is a graph illustrating VEGF stimulated production of luciferase in an HLR-ELK-1 cell line wherein he concentration of VEGF121 ~'as varied and the number of cells seeded in each well was kept constant at approximately 50,000;
Figure 4 is agraph-illustrating VEGF stimulated production of luciferase in a VEGF receptor stable transfeeted HLR-ELK-l cell line, wherein the number of cells seeded into each well was kept constant at approximately 50,000, and the concentration of VEGF121 was varied;
Figure 5 is a graph illustrating the effect of VEGF antibodies on luciferase production in a VEGF receptor cell line;
Figure 6 is a graph illustrating luciferase production in a VEGF-receptor (VEGFR) cell line wherein incubation time~was compared for 24 and 48 hours;
Figure 7 is a graph illustrating the optimal VEGF concentration for stimulation of luciferase production in a VEGF-receptor cell line;
Figure 8 is a graph illustrating the optimal time for VEGF induced luciferase production in a VEGF-receptor cell line;
Figure 9 is a graph illustrating the effect of compound ZD4190 (a known VEGF-receptor tyrosine kinase inhibitor) on VEGF stimulation of luciferase production in a VEGF-receptor cell line;
Figure 10 is a graph illustrating luciferase production after transfection of a VEGF-receptor cell line with-AdVEGF 121; and Figure 11 is a graph illustrating VEGF stimulated luciferase production using media from AdVEGF121 transfected Rat-2 cells.
-4_ DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a VEGF responsive cell-based assay and stable cell line for use therewith for determining VEGF bioactivity. The assay of the present inventionallows for the measurement of the bioactivity of VEGF
derived from biological samples including plasma; cell culture medium, tissue extracts from tissues or cells transfected with VEGF DNA sequences, or combinations thereof. The method of the present invention can also be adapted for use in high throughput screening and in secondary screens to identify novel small molecule modulators (inhibitors or activators) of a VEGF receptor, specifically FLK-1.
The assay of the present invention utilizes a stable VEGF responsive cell line which comprises HeLa cells which have been stably transfected with a reporter vector having an expressible reporter element and a DNA binding element disposed adjacent thereto. Preferably, the reporter vector includes a gene encoding a detectable gene product which is disposed downstream of a basic promoter element; preferably a TATA box, which is joined to the binding element which is preferably a GAL4 binding elements The table cell line is also transfected with a vector encoding a CMV promoter-driven ELK-1 transcription factor (which is tied to the MAP kinase pathway) and is fused to a yeast GAL4 DNA binding domain and a yeast GAL4 binding element-driven luciferase reporter construct. A third vector encoding a gene capable of expressing mouse "~
FLK-1 VEGF receptor is-also-transfected into the cells and the-stable cell line generated therefrom can be utilized to demonstrate upregulation for the detectable gene product (luciferase expression) in the presence of VEGF. That is, utilizing established signal transduction pathways, VEGF bioacti~ity can be assayed, In general; utilizing known signal transduction relationships and/or pathways, a sample to be assayed for VEGF bioactivity is placed in a container containing the stable cell line as described above: If VEGF is present in the sample, VEGF activates FLK-1 expressed by the stable cell line: Activated FLK-1, which', is a known VEGF receptor, then activates MAP kinase (Knoll and Waltenberger, J. Biol. Chem., 1997:272:32521-32527; Doanes et. al., Biochem.
Biophys. Res: Comm., 1999;255:545-548. The activated MAP kinase phosphorylates the fusion traps-activation,protein (GAL4 DNA bindixig domain [dbd] fused with ELK-1). The phosphorylated fusion protein binds to the GAL4 DNA binding site of the reported vector activating luciferase expression.
Luciferase expression can be detected utilizing techniques well-known in the art.
The presence or expression of lueiferase indicates VEGF activity in the sample.
EXAMPLES
'The following examples fiu~ther illustrate he present invention: The examples are intended merely to be illustrative of the present invention and are not to be construed as being limited:
METHODS
Cell Line Production HeLa cells stably transfected with the GAL4 luciferase reporter and a vector expressing a fusion protein composed of the GAL4 DNA binding domain and the transactivation domain of the transcription factor ELK-1 (GAL4-ELK-1-fusion) were purchased from Stratagene Inc. These cells were co-transfected with a CMV driven FLK-1 expression vector (licensed from The Ludwig Institute, Germany) and a Zeocin selection expression vector (pcDNA3.1/zeo (+), #V860-20) obtained from Invitrogen in the HeLacells. After appropriate antibiotic selection,-stable transfectants were identifiedthat respond to VEGF
by increasing,lueiferase expression.
Cell Culture and Luciferase Assay -The optimal transfected VEGF-receptor cell line (referred to as clone #5) was maintained in Dulbecco's Modified Eagle Medium (Life Technologies, Gaithersburg, MD) containing 1U% fetal bovine serum (PBS), Geneticin (250'~g/mL), Hygromysoin B (100 p.g/mL), and'Zeocin (100 ~g/mL). Cells were seeded into 24-well culture plates and allowed to attach prior to the stimulation of luciferase production by he addition of VEGF121 (298-VS-005, R&D Systems,!
Minneapolis,1VID) at the indicated concentrations. Luciferase activity was ~ 02369893 2002-O1-31 measured 24. to 48 hours poststimulation as outlined in the technical insert for the luciferase assay system available from Prornega Corporation (E1501, lVladison,' WI): The cells were washed with PBS befoie being,lysed in 200 pL of 1X
repoiter lysis buffer. The entire plate was frozen at -$0°C to increase-cell lysis. Upon thawing, 50 ~uL of the cell extract was transferred into a 96-well plate.
Luciferase assay reagent (100 ~L) was auto-injected, and light production was measured using a microplate luminometer.
Effect of Serum Preincubation Conditions on Luciferase Activity Cells'were seeded into wells 24 hours prior to VEGF addition: The cells' were harvested 48 hours after the addition of 25 ng/mL of VEGF. Cells were pre-incubated under various serum conditions: (1) 10% FBS; (2) 0:2% FBS, (3) serum free; and (4) nutridoma; a serum '-free media supplement: The results are shown in Figure 1 a. The optimal serum pre-incubation condition was found to be pre-incubation in l U% FBS. An identified experiment was performed except that the concentration of VEGF added was increased o 50 ng/mL. The results are hown in Figure 1b. The increased concentrations of VEGF was found o increase luciferase expression.
Effects of Cell density and VEisF121 Concentration on Luciferase E%pression _ _-_._ __~ _ _ _._ ._ ___ _ _ Cells were prepared as described abo~re. Cells were seeded into wells 24 hours prior to the addition of WEGF 121, VEGF 121 ~'as added to the cells at concentrations of 25 and 50 ng/mL, respectively. Cells seeded into the wells were tested at densities of 50; 100, 150, and 200 KJwell: The results are shown in Figure 2: r Dose Response to VEGF in the Parental Cell Line (HLR-ELK-1) Cells were prepared as described above.50 K7we11 were seeded and kept in 1U% FBS throughout the experiment. VEGF121 was added 24 hours after seeding, and the cells were harvested and analysed 48 hours after the addition of VEGF121. The results are shown in Figure 3: The results showed thatthe parental cell line was, no more responsive to vEGFi21 stimulation than the control.
Dose Response of VEGF-Receptor Stable Transfected HLR-ELKl: Cell Line Cells were prepaxed as' described above. Cells were transfected with he plasmid vector expressing the FLK-i VEGF receptor were seeded at SU K/well and maintained in 10% FBS throughout the experiment. VEGF 121 was added 24 hours after seeding, and the cElls were harvested 48 hours after the addition of VEGF 121: The concentration of VEGF:121 ~~ tested at 10, 25; 50; 75, 100; and 150 ngJmL. Maximum increase in luciferase expression was found at a VEGF121 concentration of 100 ng/mL as shown in Figure 4.
Dose Responsive Specificity of the VEGF-Receptor Cell Line To=demonstrate the dose responsive specificity of the VEGF-receptor cell line, cells were prepared-as described above: The ransfected cells were"
incubated with VEGFI2l ~ ~e adenovirus NULL vector (AdCLX), antihuman VEGF121 antibodies (AF-293-NA [polyclonal]; MAB293 [monoclonal]; R&D Systems), a VEGF receptor-specific tyrosine kinase inhibitor (ZD4190; Zeneca [Wedge S.R.;
Ogilvie I7.J. Inhibition of VEGF signal transduction: Identification of ZD4190.
Adv. Exp: fed Biol.; 200U;476(Angiogenesis: From the Molecular to Integrative Pharmacology):307-310; and Wedge S,R.; Ogilvie D., Dukes M.; Kendrew J.;
Curwen J.O.; Hennequin L.F., Thomas A.P.; et. al., ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res.; 2000;60(4):970-975]), media from ADVEGF121 f0 transfected rat 2 cells at various concentrations, or the VEGF-receptor cell line ~ 02369893 2002-O1-31 -g-was directly infected with an adenovirus containing VEGF 121 (AdGV 121.10, CI-1023, GenVec, Inc., Rockville, MD) at carious concentrations.
Cells were seeded at 50 K/well 24 hours prior to the addition of VEGF/anti-VEGF and were collected 48 hours later. Referring to Figure 5, the results for the antihuman VEGF antibodies' are shown. The polyclonal antibodies did-not significantly affect luciferase expression. The monoclonal antibodies at the 1:100 and 1:1000 dilutions affected the luciferase expression:
Figure 9 shows he effects of the known VEGF receptor tyrosine kinase' inhibitor (ZD4190) on luciferase expression. The VEGF receptor tyrosine kinase inhibitor affected luciferase expression in a dose-response manner.
Figure l0 shows the effects of AdVEGF 12l obtained from using a media from AdVEGF121 tr'ansfected rat 2 cells. The addition of AdVEGFI2I to the VEGF-receptor cell line affected luciferase expression in a close response manner both from the AdVEGF121 itself and from the media from AdVEGF121 transfected rat 2 cells.
Luciserase Production in VEGF-Receptor Cell Line at 24 and 48 Hours After the Addition'of VEGF
Cells were prepared as described above. VEGF 121 was added to cells (50 K/well) 24 hours after seeding. VEGF 121 was added o the cells at concentrations of either 25 or SO ng/mL,. Luciferase expression was measured 24 hours after,the addition of VEGF121 and 48 hours after he addition of VEGF121. The results are shown in Figure 6. Maximum luciferase expression was found in the cells treated with SO ng/mL of VEGF121 at 24 hours post-VEGF121 introduction.
Determination of Optimal VEGF Concentration VEGF-receptor cells were seeded at SO K/well and incubated in 10% FBS
throughout the experiment. VEGFl2l was added to the cells 24 hours after _9r seeding, and the cells were harvested 1'8 hours later. The VEGF 121 was applied to the cells at the following concentrations: 1, 5; 10, and 2U0 ng/mL. The results acre shown in Figure 7. The optimal VEGF121 concentration ranges from approximately SU nglmL to approximately 2p0 ng/mL:
_ ExAl~IPLE 8 Optimal Incubation Time for VEGF-Induced Luciferase Production Cells were prepared as described above VEGF-receptor cells were seeded at 50 K/vvell and incubated for 24 hours in 1 Q% FBS prior to the addition of VEGF 121. Cells were harvested at 05; l, 2, 3, 4, 5; 67, 8,18, and 24 hours, after VEGF 121: ~2S ng/mL) addition. Figure 8 shows the results of this experiment.
Approximately l 8 hours of expression time was found to yield maximum luciferase 'expression (production).
All publications mentioned in the specification are herein incorporated b reference to the same extent as if each independent publication vvas specifically and individually indicated to be incorporated by reference.
While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications'. The application is intended to cover any variations, uses; or adaptations following, in general; the principles of the invention and including such departures from the present disclosure within known or customary practice within the art to which the invention pertains and may be applied to the ;essential features herein before set forth:
Figure 3 is a graph illustrating VEGF stimulated production of luciferase in an HLR-ELK-1 cell line wherein he concentration of VEGF121 ~'as varied and the number of cells seeded in each well was kept constant at approximately 50,000;
Figure 4 is agraph-illustrating VEGF stimulated production of luciferase in a VEGF receptor stable transfeeted HLR-ELK-l cell line, wherein the number of cells seeded into each well was kept constant at approximately 50,000, and the concentration of VEGF121 was varied;
Figure 5 is a graph illustrating the effect of VEGF antibodies on luciferase production in a VEGF receptor cell line;
Figure 6 is a graph illustrating luciferase production in a VEGF-receptor (VEGFR) cell line wherein incubation time~was compared for 24 and 48 hours;
Figure 7 is a graph illustrating the optimal VEGF concentration for stimulation of luciferase production in a VEGF-receptor cell line;
Figure 8 is a graph illustrating the optimal time for VEGF induced luciferase production in a VEGF-receptor cell line;
Figure 9 is a graph illustrating the effect of compound ZD4190 (a known VEGF-receptor tyrosine kinase inhibitor) on VEGF stimulation of luciferase production in a VEGF-receptor cell line;
Figure 10 is a graph illustrating luciferase production after transfection of a VEGF-receptor cell line with-AdVEGF 121; and Figure 11 is a graph illustrating VEGF stimulated luciferase production using media from AdVEGF121 transfected Rat-2 cells.
-4_ DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a VEGF responsive cell-based assay and stable cell line for use therewith for determining VEGF bioactivity. The assay of the present inventionallows for the measurement of the bioactivity of VEGF
derived from biological samples including plasma; cell culture medium, tissue extracts from tissues or cells transfected with VEGF DNA sequences, or combinations thereof. The method of the present invention can also be adapted for use in high throughput screening and in secondary screens to identify novel small molecule modulators (inhibitors or activators) of a VEGF receptor, specifically FLK-1.
The assay of the present invention utilizes a stable VEGF responsive cell line which comprises HeLa cells which have been stably transfected with a reporter vector having an expressible reporter element and a DNA binding element disposed adjacent thereto. Preferably, the reporter vector includes a gene encoding a detectable gene product which is disposed downstream of a basic promoter element; preferably a TATA box, which is joined to the binding element which is preferably a GAL4 binding elements The table cell line is also transfected with a vector encoding a CMV promoter-driven ELK-1 transcription factor (which is tied to the MAP kinase pathway) and is fused to a yeast GAL4 DNA binding domain and a yeast GAL4 binding element-driven luciferase reporter construct. A third vector encoding a gene capable of expressing mouse "~
FLK-1 VEGF receptor is-also-transfected into the cells and the-stable cell line generated therefrom can be utilized to demonstrate upregulation for the detectable gene product (luciferase expression) in the presence of VEGF. That is, utilizing established signal transduction pathways, VEGF bioacti~ity can be assayed, In general; utilizing known signal transduction relationships and/or pathways, a sample to be assayed for VEGF bioactivity is placed in a container containing the stable cell line as described above: If VEGF is present in the sample, VEGF activates FLK-1 expressed by the stable cell line: Activated FLK-1, which', is a known VEGF receptor, then activates MAP kinase (Knoll and Waltenberger, J. Biol. Chem., 1997:272:32521-32527; Doanes et. al., Biochem.
Biophys. Res: Comm., 1999;255:545-548. The activated MAP kinase phosphorylates the fusion traps-activation,protein (GAL4 DNA bindixig domain [dbd] fused with ELK-1). The phosphorylated fusion protein binds to the GAL4 DNA binding site of the reported vector activating luciferase expression.
Luciferase expression can be detected utilizing techniques well-known in the art.
The presence or expression of lueiferase indicates VEGF activity in the sample.
EXAMPLES
'The following examples fiu~ther illustrate he present invention: The examples are intended merely to be illustrative of the present invention and are not to be construed as being limited:
METHODS
Cell Line Production HeLa cells stably transfected with the GAL4 luciferase reporter and a vector expressing a fusion protein composed of the GAL4 DNA binding domain and the transactivation domain of the transcription factor ELK-1 (GAL4-ELK-1-fusion) were purchased from Stratagene Inc. These cells were co-transfected with a CMV driven FLK-1 expression vector (licensed from The Ludwig Institute, Germany) and a Zeocin selection expression vector (pcDNA3.1/zeo (+), #V860-20) obtained from Invitrogen in the HeLacells. After appropriate antibiotic selection,-stable transfectants were identifiedthat respond to VEGF
by increasing,lueiferase expression.
Cell Culture and Luciferase Assay -The optimal transfected VEGF-receptor cell line (referred to as clone #5) was maintained in Dulbecco's Modified Eagle Medium (Life Technologies, Gaithersburg, MD) containing 1U% fetal bovine serum (PBS), Geneticin (250'~g/mL), Hygromysoin B (100 p.g/mL), and'Zeocin (100 ~g/mL). Cells were seeded into 24-well culture plates and allowed to attach prior to the stimulation of luciferase production by he addition of VEGF121 (298-VS-005, R&D Systems,!
Minneapolis,1VID) at the indicated concentrations. Luciferase activity was ~ 02369893 2002-O1-31 measured 24. to 48 hours poststimulation as outlined in the technical insert for the luciferase assay system available from Prornega Corporation (E1501, lVladison,' WI): The cells were washed with PBS befoie being,lysed in 200 pL of 1X
repoiter lysis buffer. The entire plate was frozen at -$0°C to increase-cell lysis. Upon thawing, 50 ~uL of the cell extract was transferred into a 96-well plate.
Luciferase assay reagent (100 ~L) was auto-injected, and light production was measured using a microplate luminometer.
Effect of Serum Preincubation Conditions on Luciferase Activity Cells'were seeded into wells 24 hours prior to VEGF addition: The cells' were harvested 48 hours after the addition of 25 ng/mL of VEGF. Cells were pre-incubated under various serum conditions: (1) 10% FBS; (2) 0:2% FBS, (3) serum free; and (4) nutridoma; a serum '-free media supplement: The results are shown in Figure 1 a. The optimal serum pre-incubation condition was found to be pre-incubation in l U% FBS. An identified experiment was performed except that the concentration of VEGF added was increased o 50 ng/mL. The results are hown in Figure 1b. The increased concentrations of VEGF was found o increase luciferase expression.
Effects of Cell density and VEisF121 Concentration on Luciferase E%pression _ _-_._ __~ _ _ _._ ._ ___ _ _ Cells were prepared as described abo~re. Cells were seeded into wells 24 hours prior to the addition of WEGF 121, VEGF 121 ~'as added to the cells at concentrations of 25 and 50 ng/mL, respectively. Cells seeded into the wells were tested at densities of 50; 100, 150, and 200 KJwell: The results are shown in Figure 2: r Dose Response to VEGF in the Parental Cell Line (HLR-ELK-1) Cells were prepared as described above.50 K7we11 were seeded and kept in 1U% FBS throughout the experiment. VEGF121 was added 24 hours after seeding, and the cells were harvested and analysed 48 hours after the addition of VEGF121. The results are shown in Figure 3: The results showed thatthe parental cell line was, no more responsive to vEGFi21 stimulation than the control.
Dose Response of VEGF-Receptor Stable Transfected HLR-ELKl: Cell Line Cells were prepaxed as' described above. Cells were transfected with he plasmid vector expressing the FLK-i VEGF receptor were seeded at SU K/well and maintained in 10% FBS throughout the experiment. VEGF 121 was added 24 hours after seeding, and the cElls were harvested 48 hours after the addition of VEGF 121: The concentration of VEGF:121 ~~ tested at 10, 25; 50; 75, 100; and 150 ngJmL. Maximum increase in luciferase expression was found at a VEGF121 concentration of 100 ng/mL as shown in Figure 4.
Dose Responsive Specificity of the VEGF-Receptor Cell Line To=demonstrate the dose responsive specificity of the VEGF-receptor cell line, cells were prepared-as described above: The ransfected cells were"
incubated with VEGFI2l ~ ~e adenovirus NULL vector (AdCLX), antihuman VEGF121 antibodies (AF-293-NA [polyclonal]; MAB293 [monoclonal]; R&D Systems), a VEGF receptor-specific tyrosine kinase inhibitor (ZD4190; Zeneca [Wedge S.R.;
Ogilvie I7.J. Inhibition of VEGF signal transduction: Identification of ZD4190.
Adv. Exp: fed Biol.; 200U;476(Angiogenesis: From the Molecular to Integrative Pharmacology):307-310; and Wedge S,R.; Ogilvie D., Dukes M.; Kendrew J.;
Curwen J.O.; Hennequin L.F., Thomas A.P.; et. al., ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res.; 2000;60(4):970-975]), media from ADVEGF121 f0 transfected rat 2 cells at various concentrations, or the VEGF-receptor cell line ~ 02369893 2002-O1-31 -g-was directly infected with an adenovirus containing VEGF 121 (AdGV 121.10, CI-1023, GenVec, Inc., Rockville, MD) at carious concentrations.
Cells were seeded at 50 K/well 24 hours prior to the addition of VEGF/anti-VEGF and were collected 48 hours later. Referring to Figure 5, the results for the antihuman VEGF antibodies' are shown. The polyclonal antibodies did-not significantly affect luciferase expression. The monoclonal antibodies at the 1:100 and 1:1000 dilutions affected the luciferase expression:
Figure 9 shows he effects of the known VEGF receptor tyrosine kinase' inhibitor (ZD4190) on luciferase expression. The VEGF receptor tyrosine kinase inhibitor affected luciferase expression in a dose-response manner.
Figure l0 shows the effects of AdVEGF 12l obtained from using a media from AdVEGF121 tr'ansfected rat 2 cells. The addition of AdVEGFI2I to the VEGF-receptor cell line affected luciferase expression in a close response manner both from the AdVEGF121 itself and from the media from AdVEGF121 transfected rat 2 cells.
Luciserase Production in VEGF-Receptor Cell Line at 24 and 48 Hours After the Addition'of VEGF
Cells were prepared as described above. VEGF 121 was added to cells (50 K/well) 24 hours after seeding. VEGF 121 was added o the cells at concentrations of either 25 or SO ng/mL,. Luciferase expression was measured 24 hours after,the addition of VEGF121 and 48 hours after he addition of VEGF121. The results are shown in Figure 6. Maximum luciferase expression was found in the cells treated with SO ng/mL of VEGF121 at 24 hours post-VEGF121 introduction.
Determination of Optimal VEGF Concentration VEGF-receptor cells were seeded at SO K/well and incubated in 10% FBS
throughout the experiment. VEGFl2l was added to the cells 24 hours after _9r seeding, and the cells were harvested 1'8 hours later. The VEGF 121 was applied to the cells at the following concentrations: 1, 5; 10, and 2U0 ng/mL. The results acre shown in Figure 7. The optimal VEGF121 concentration ranges from approximately SU nglmL to approximately 2p0 ng/mL:
_ ExAl~IPLE 8 Optimal Incubation Time for VEGF-Induced Luciferase Production Cells were prepared as described above VEGF-receptor cells were seeded at 50 K/vvell and incubated for 24 hours in 1 Q% FBS prior to the addition of VEGF 121. Cells were harvested at 05; l, 2, 3, 4, 5; 67, 8,18, and 24 hours, after VEGF 121: ~2S ng/mL) addition. Figure 8 shows the results of this experiment.
Approximately l 8 hours of expression time was found to yield maximum luciferase 'expression (production).
All publications mentioned in the specification are herein incorporated b reference to the same extent as if each independent publication vvas specifically and individually indicated to be incorporated by reference.
While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications'. The application is intended to cover any variations, uses; or adaptations following, in general; the principles of the invention and including such departures from the present disclosure within known or customary practice within the art to which the invention pertains and may be applied to the ;essential features herein before set forth:
Claims (14)
1. A method for determining vascular endothelial growth factor (VEGF) activity in a sample, said method comprising the steps of:
contacting a sample to be assayed for VEGF activity with a stable cell line comprising cells transfected with a reporter vector having an expressible reporter element and a DNA binding site disposed adjacent hereto, a chimeric transactivatable vector comprising a gene encoding a phosphorylatable protein and a DNA binding domain which specifically binds to the DNA binding site, and an expression vector encoding a gene for a VEGF receptor detecting the presence of expressed reporter element indicating VEGF
activity; and detecting expression of the reporter element, wherein expression of the reporter element indicates VEGF activity.
contacting a sample to be assayed for VEGF activity with a stable cell line comprising cells transfected with a reporter vector having an expressible reporter element and a DNA binding site disposed adjacent hereto, a chimeric transactivatable vector comprising a gene encoding a phosphorylatable protein and a DNA binding domain which specifically binds to the DNA binding site, and an expression vector encoding a gene for a VEGF receptor detecting the presence of expressed reporter element indicating VEGF
activity; and detecting expression of the reporter element, wherein expression of the reporter element indicates VEGF activity.
2. A method according to Claim 1, wherein the reporter vector further comprises a GAL4 binding element.
3. A method according to Claim 1, wherein the phosphorylatable protein encoded by chimeric transactivatable vector can be phophorylated by MAPK.
4. A method according to Claim 1, wherein the phosphorylatable protein comprises ELK-1
5. A method according to Claim 1, wherein VEGF receptor comprises FLK-1.
-1l-
-1l-
6. A method according to Claim 1, wherein said contacting step further comprises binding VEGF present in the sample with expressed VEGF
receptor.
receptor.
7. A method according to Claim 6, wherein said including contacting step further comprises activating MAPK with he expressed VEGF receptor.
8. A method according to Claim 7, further comprising the step of expressing the trans-activator vector to produce a chimeric product comprising the phosphorylatable protein and DNA binding domain.
9. A method according to Claim 8, further comprising the step of phosphorylating the chimeric product with the activated MAPK.
10. A method according to Claim 9, further comprising the step of binding the phosphorylated chimeric product to the DNA binding site of the reporter vector, wherein expression of the expressible reporter element is activated indicating the presence of VEGF in the sample.
11. A method for determining whether a candidate compound is useful for modulating VEGF activity, said method comprising the steps of:
(a) providing a cell expressing VEGF;
(b) contacting the cell with a candidate compound;
(c) measuring VEGF activity according to Claim 1, wherein altered VEGF
activity relative to a cell not contacted with the candidate compound indicates that the candidate compound modulates VEGF activity.
(a) providing a cell expressing VEGF;
(b) contacting the cell with a candidate compound;
(c) measuring VEGF activity according to Claim 1, wherein altered VEGF
activity relative to a cell not contacted with the candidate compound indicates that the candidate compound modulates VEGF activity.
12. A method according to Claim 11, wherein the reporter vector further comprises a GAL4 binding element.
13. A method of determining whether a candidate compound is useful for modulating VEGF receptor activity, said method comprising the steps of:
(a) providing a cell expressing the VEGF receptor FLK-1;
(b) contacting the cell with a candidate compound;
(c) measuring VEGF receptor activity, wherein the altered VEGF receptor activity relative to a cell not contacted with the candidate compound, indicates that the candidate compound modulates VEGF receptor activity.
(a) providing a cell expressing the VEGF receptor FLK-1;
(b) contacting the cell with a candidate compound;
(c) measuring VEGF receptor activity, wherein the altered VEGF receptor activity relative to a cell not contacted with the candidate compound, indicates that the candidate compound modulates VEGF receptor activity.
14. A stable cell line transfected with a reporter vector encoding a luciferase gene and a GAL4 DNA binding site; a chimeric transactivator vector encoding for an ELK-1/GAL4 DNA binding domain fusion protein; and a vector encoding for VEGF receptor FLK-1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26820201P | 2001-02-12 | 2001-02-12 | |
| US60/268,202 | 2001-02-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2369893A1 true CA2369893A1 (en) | 2002-08-12 |
Family
ID=23021917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002369893A Abandoned CA2369893A1 (en) | 2001-02-12 | 2002-01-31 | Vegf responsive cell-based assay for determining vegf bioactivity |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US6787323B2 (en) |
| EP (1) | EP1233074A1 (en) |
| JP (1) | JP2002335998A (en) |
| CA (1) | CA2369893A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7595149B1 (en) | 2004-11-08 | 2009-09-29 | University Of Kentucky Research Foundation | Methods for cancer detection |
| US9079953B2 (en) | 2009-06-17 | 2015-07-14 | Abbvie Biotherapeutics Inc. | Anti-VEGF antibodies and their uses |
| WO2012012708A1 (en) * | 2010-07-22 | 2012-01-26 | Regents Of The University Of Minnesota | Induced pluripotent stem cells |
| US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1701814A (en) * | 1992-11-13 | 2005-11-30 | 马克斯普朗克科学促进协会 | F1K-1 is a receptor for vascular endothelial growth factor |
| US5981569A (en) * | 1992-11-13 | 1999-11-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease |
-
2002
- 2002-01-31 CA CA002369893A patent/CA2369893A1/en not_active Abandoned
- 2002-02-05 EP EP02002610A patent/EP1233074A1/en not_active Withdrawn
- 2002-02-07 US US10/072,767 patent/US6787323B2/en not_active Expired - Fee Related
- 2002-02-08 JP JP2002032736A patent/JP2002335998A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20020110830A1 (en) | 2002-08-15 |
| US6787323B2 (en) | 2004-09-07 |
| EP1233074A1 (en) | 2002-08-21 |
| JP2002335998A (en) | 2002-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1012324B1 (en) | Promiscuous g-protein compositions and their use | |
| Patik et al. | Functional expression of the 11 human Organic Anion Transporting Polypeptides in insect cells reveals that sodium fluorescein is a general OATP substrate | |
| Sinha et al. | Role of TRAF3 and-6 in the activation of the NF-κB and JNK pathways by X-linked Ectodermal Dysplasia Receptor | |
| Ukegawa et al. | Growth-promoting effect of muscarinic acetylcholine receptors in colon cancer cells | |
| IE77332B1 (en) | Method of screening for protein inhibitors and activators | |
| Uehara et al. | Novel high-throughput screening system for identifying STAT3–SH2 antagonists | |
| Sundvall et al. | Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains | |
| Rao et al. | Polyamines regulate Rho-kinase and myosin phosphorylation during intestinal epithelial restitution | |
| WO2003027634A2 (en) | Identification of modulatory molecules using inducible promoters | |
| O'Kelly et al. | Functional domains of CCN1 (Cyr61) regulate breast cancer progression | |
| JP4614954B2 (en) | Method for detecting methyltransferase activity and method for screening for methyltransferase activity regulator | |
| US20070178537A1 (en) | Assays for detection of bioactive compounds that interact with heat shock protein 90 | |
| US6787323B2 (en) | VEGF responsive cell-based assay for determining VEGF bioactivity | |
| US20170138958A1 (en) | Method for measuring anti-wt1 antibody | |
| AU2004299647A1 (en) | Methods of identifying, selecting and/or characterizing compounds which modulate the activity of a Src family kinase | |
| CA2408297A1 (en) | Cancer diagnosis and assays for screening anti-cancer agents | |
| Clerc et al. | Propensity for HBZ-SP1 isoform of HTLV-I to inhibit c-Jun activity correlates with sequestration of c-Jun into nuclear bodies rather than inhibition of its DNA-binding activity | |
| Mortier et al. | The focal adhesion targeting sequence is the major inhibitory moiety of Fak-related non-kinase | |
| Du et al. | Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor β | |
| US7029905B1 (en) | Method for the cellular high-throughput-detection of receptor ligand interactions | |
| Wu et al. | Mutual regulation between deubiquitinase CYLD and retroviral oncoprotein Tax | |
| Lemos et al. | Tetrameric, active PKM2 inhibits IP3 receptors, potentially requiring GRP75 as an additional interaction partner | |
| US7348151B1 (en) | Method for the cellular high-throughput-detection of nuclear receptor ligand interactions | |
| EP1945782A2 (en) | Detection of intracellular enzyme complex | |
| AU2003259498A1 (en) | Inducible focal adhesion kinase cell assay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |